Studies have demonstrated that AR is expressed in up to 50% of TNBC cases [54], and its inhibition has been shown to decrease cancer stem cell populations and tumor initiation, suggesting a potential target for overcoming resistance to chemotherapy. The gene discussed is AR; the disease is cancer.